Don’t just see the disease, quantify it
Mosaic is an all encompassing software platform for quantitative analysis of computed tomography angiography (CTA) scans.
Cleared for use in all forms of atherosclerosis and aneurysmal disease.
Analyse the coronary arteries, carotid arteries, aorta, and peripheral arteries.
Provides highly streamlined analysis of anatomy and risk from CTA scans.
Automated tools for stenosis, atherosclerotic plaque and CAD-RADS.
Mosaic V1 is cleared for use in the US by the FDA.
This initial version brings efficient quantitative analysis of CTA scans and offers streamlined analysis of stenosis and atherosclerotic plaque characteristics such as volume and type, and high-risk plaque features like spotty calcification, low attenuating plaque and proximal remodelling. The software enables high-quality clinical reporting and provides CAD-RADS results.
We will soon be releasing our automated coronary plaque module, followed by novel features we are bringing to the clinic.
In addition to clinical products, Mosaic Research Edition offers a wide range of benefits over existing solutions enabling research from small scale multi-modality imaging studies, large scale clinical trial analyses, and an “all-in-one” image analysis and simulation platform. Get in touch to find out more.
Built on science,
designed for the clinic
Mosaic is your comprehensive platform for analysing cardiovascular disease.
Mosaic analyses CTA scans and is validated for use with all major CT scanner manufacturers and DICOM formats, and offers precise measurements of all forms of anatomy and arterial diseases.
Underpinning Mosaic is a foundation of multi-modality imaging in the form of invasive optical coherence tomography (OCT), sodium fluoride positron emission tomography (NaF-PET), and coronary angiography, and by registering these images together we’ve been able to unlock new insights into arterial disease.
We are developing exciting new methods to reveal the patients at highest risk of future adverse events, enabling never seen before insights into early-stage disease activity and risk of future heart attack.
Mosaic will provide not only a detailed assessment of the atherosclerotic plaque in the artery as well as the region of restricted blood flow, but also markers of heart failure and overall risk – allowing better-informed decisions that drive better patient outcomes.
Benefits:
To patients
- Learn about your current condition
- Understand your future risk
- Receive personalised treatment, rather than generalised management
- Avoid potentially unnecessary invasive procedures and low-value tests
To physicians
- A complete assessment of your patient’s condition
- Understand the ‘now’ and ‘then’ of your patient
- Interactive high-fidelity 3D models
- Deep quantitative insight into current disease profile
- Make better informed clinical management decisions
To payers
- Fully harness the power of CTA
- No capital expense
- Utilise AI-enhanced workflows to increase throughput and prioritise the high-risk cases
- Established reimbursement pathways (CPT codes) available in the US
- Reduce downstream tests and costs
- Bring state-of-the-art technology into your clinics
To researchers
- Streamline your clinical research of CTA analysis of arterial diseases to increase throughput
- Obtain quantitative data without the manual image analysis workload, including background batch processing
- Study the effects of drugs and interventions on arterial disease
- Enhance medical device design with sophisticated analysis of CTA